Clinical Trials Directory

We are doing this study to find out if an investigational drug called HM43239 (the study drug) is a safe and effective option for people who have AML that came back after remission or did not respond to standard treatments. We also want to find out what dose of the study drug works best for most patients.

We are doing this study to learn more about children with atrioventricular septal defect. We hope to improve care for patients with this condition in the future.

We are doing this study to find out if giving a drug called Exparel (the study drug) as a spinal injection is a safe and effective option for pain management. The study drug is approved to treat pain after surgery and is injected into the surrounding area where the surgery was done. We want to know if the study drug can also be given as an intrathecal (into the space surrounding the spine) injection to help control pain.

If you choose to join this study, you will get a random assignment to 1 of 2 groups:
- One group will the study drug in combination with sunitinib
- The other group will get a placebo (inactive substance that has no drug in it) in combination with sunitinib

No matter to which group you are assigned, during the study you will:
- Have physical exams, electrocardiograms (ECG), and blood draws
- Have CT or MRI scans

You will visit our clinic for follow-up visits after you stop taking the study drugs, and we will keep in touch with you to see how you are feeling.

We are doing this study to find out whether hepatic artery infusion (HAI) pump therapy with floxuridine and dexamethasone is an effective treatment for cholangiocarcinoma that cannot be removed with surgery and has not been treated yet. We want to find out whether the HAI pump treatment plus GemOx chemotherapy works as well as or better than GemOx alone at extending the time before your disease gets worse.

We are doing this study to find out if the study drug, patritumab deruxtecan, can be measured in brain tumor tissue after a single dose is given before surgery to remove brain metastases.

We are doing this study to compare the standard treatments (FOLFOX or CAPOX after chemoradiation) for rectal cancer to a drug regimen called FOLFIRINOX that is given after chemoradiation. We want to know if FOLFIRINOX after chemoradiation can provide better outcomes than either of the 2 standard treatments.

We are doing this study to find out if using Radium-223 dichloride (the study drug) in combination with cabozantinib is a safe and effective treatment for advanced RCC that has spread to the bone. We want to know if this combination is potentially better than the standard treatment of cabozantinib on its own.